This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Reed, E. Articles by Poirier, M. C. Search for Related Content PubMed PubMed Citation Articles by Reed, E. Articles by Poirier, M. C.

Evaluation of Platinum-DNA Adduct Levels Relative to Known Prognostic Variables in a Cohort of Ovarian Cancer Patients

Division of Cancer Treatment [E. R., Y. O., S. M. S.] and Division of Cancer Etiology [S. H. Y., M. C. P.], National Cancer Institute, Bethesda, Maryland 20892, and Fox Chase Cancer Center, Philadelphia, Pennsylvania 19111 [R. C. Y., R. F. O.]

Single-agent chemotherapy with cisplatin or carboplatin can induce remissions in approximately 30% of previously treated patients with advanced stage ovarian cancer. Previous studies have shown that the extent of platinum-DNA adduct formation measured in WBC DNA of ovarian cancer patients treated with cisplatin or carboplatin is directly associated with disease response (Reed et al., Proc. Natl. Acad. Sci. USA, 84: 5024–5028, 1987). It has been unclear whether adduct level in WBC DNA is independent of known prognostic variables in this disease, or whether adduct level parallels a known prognostic variable that can be more easily monitored. In a cohort of 24 ovarian cancer patients treated with single-agent cisplatin or carboplatin, we retrospectively assessed the relationship between disease response, platinum-DNA adducts in WBC DNA, and each of eight prognostic variables by both univariate analysis and multivariate analysis. The prognostic variables evaluated included: response to previous treatment, Karnofsky status, total platinum dose prior to current therapy, stage of disease, age, bulk of disease at initiation of therapy, histological type, and histological grade. By univariate analysis, adduct level was strongly associated with disease response (two-sided P = 0.0058), with the next strongest associations with disease response being held by Karnofsky status (P = 0.125), stage of disease (P = 0.189), response to previous treatment (P = 0.352), total previous platinum dose (P = 0.358), and age (P = 0.374). No significant associations were found between adduct level and histological type or histological grade. Further, when patients were stratified by the number of cycles studied (one cycle, two cycles, or three cycles), higher levels of adduct were consistently seen in those patients responding to therapy. We conclude that, in this small cohort of refractory ovarian cancer patients treated with single-agent cisplatin or carboplatin, adduct level in WBC DNA appears to be more closely related to disease response than other previously identified prognostic variables.

¹ To whom requests for reprints should be addressed, at Medicine Branch, National Cancer Institute, Building 10, Room 6N119, Bethesda, MD 20892.

Received 8/ 8/89. Revised 11/27/89.

This article has been cited by other articles:

				K. M. Darcy, C. Tian, and E. Reed A Gynecologic Oncology Group Study of Platinum-DNA Adducts and Excision Repair Cross-Complementation Group 1 Expression in Optimal, Stage III Epithelial Ovarian Cancer Treated with Platinum-Taxane Chemotherapy Cancer Res., May 1, 2007; 67(9): 4474 - 4481. [Abstract] [Full Text] [PDF]

				G. J. Veal, C. Dias, L. Price, A. Parry, J. Errington, J. Hale, A. D. J. Pearson, A. V. Boddy, D. R. Newell, and M. J. Tilby Influence of Cellular Factors and Pharmacokinetics on the Formation of Platinum-DNA Adducts in Leukocytes of Children Receiving Cisplatin Therapy Clin. Cancer Res., August 1, 2001; 7(8): 2205 - 2212. [Abstract] [Full Text] [PDF]